ClinicalTrials.gg
CompletedNCT02130414CYC102Updated May 19, 2015

PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects

A Phase 1 interventional study of Sandimmun® IV and CyCol® capsules in Healthy, sponsored by Sigmoid Pharma. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-19.

Sponsored by Sigmoid Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The aim of this Phase I, single centre, multi stage study is to evaluate the safety, tolerability, pharmacokinetics and relative colonic mucosal concentrations of cyclosporine capsules (CyCol®) compared to intravenous cyclosporine in healthy male volunteers.

Read the detailed description

This is an open label, multiple-dose, multi-stage pharmacokinetic (PK) study. A maximum of 40 healthy adult male volunteers aged between 18 and 55 years will be enrolled at a single clinical research unit.

For each CyCol® group dosing will last 7 days, whilst the Sandimmun® IV group will have a single dose over 24 hours.

Single dose pharmacokinetics of different doses of CyCol® will be compared to IV Sandimmun®. In addition colonic tissue concentrations will be compared after multiple doses of CyCol® to a single IV dose of Sandimmun®. Concentrations of unchanged cyclosporine and it's metabolites in the faeces will also be explored.

Stage 1 of the study will investigate the 75mg dose (OD and BID) of CyCol® and IV Sandimmun®. Then dependent on results Stages 2 and 3 will investigate either lower (37.5mg) or higher (150mg) dose levels. The dosing regimens chosen for Stages 2 and 3 will be based upon safety and tolerability, systemic exposure and colonic mucosa tissue concentrations observed at other doses.

02

Conditions studied

  • Healthy

Keywords

  • Cyclosporine
  • Healthy Volunteers
  • Immunosuppressive Agents
  • CyCol
  • Pharmacokinetics
03

In context

Lead sponsor

Sigmoid Pharma is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers, between the ages of 18 and 55 years, inclusive.
  • Mass Index () of 18.5 to 30.0 kg/m2, inclusive; and a total body weight >50 kg (110 lbs).
  • Subjects capable of providing written consent.
  • Subjects willing to use acceptable method of starting from the first dose and continuing for at least 3 months after the last dose of study drug.
  • Subjects who are willing and able to comply with scheduled visits, dosing plan, laboratory tests, and other study procedures.
  • Subjects must have a regular bowel movement

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
  • History of significant drug abuse
  • History of regular alcohol consumption
  • Treatment with an drug within 90 days prior to first dose of study medication.
  • If considered by the Investigator, screening supine blood pressure 140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
  • 12-lead demonstrating interval >450 msec or a QRS interval >120 msec at Screening.
  • Use of medications :

    • prescription medications (oral and topical) within 14 days prior to first dosing.
    • over-the-counter products including herbal and food supplements within 7 days prior to first dose of study medication
    • injection or implant of any drug within 3 months prior to first dose of study medication
  • Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
  • Plasma donation within 7 days prior to dosing.
  • History of sensitivity to cyclosporine or other related drugs.
  • Subjects with evidence of ongoing (active or carrier status) or C, or (HIV) infection upon serological testing.
  • History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to Quantiferon test performed at screening.
  • Positive Quantiferon test result
  • Subjects who have received or are planning to receive any within 28 days prior to the first dose of study medication, or planning to receive a vaccination during the course of the study.
  • Any evidence of active infection or febrile illness within 7 days of the first dose of study medication
  • Presence of fever (body temperature >37.6oC) within 2 weeks prior to first dose of study medication.
  • Subjects who are unwilling to refrain from consumption of grapefruit or products containing grapefruit juice or grapefruit-related citrus fruits (eg, starfruit, pomelos) from 7 days prior to the first dose of study medication until completion of all study procedures.
  • Unwilling or unable to comply with the guidelines described in this protocol, or a reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Sandimmun® IV

    Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)

    Drug: Sandimmun® IV

  • Experimental
    CyCol® capsules

    CyCol®: 75 mg OD \& BID for 7 days

    Drug: CyCol® capsules

  • Experimental
    CyCol® capsules 37.5 mg

    CyCol®: 37.5 mg OD or BID for 7 days

    Drug: CyCol® capsules

  • Experimental
    CyCol® capsules, 150 mg

    CyCol®: 150 mg OD or BID for 7 days

    Drug: CyCol® capsules

Interventions

  • 2 mg/kg IV

    Also known as: Cyclosporine A, Sandimmun® concentrate for solution for Infusion

  • 37.5 mg CyCol® capsules

    Also known as: Cyclosporine A, oral cyclosporine

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic variables for cyclosporine (in whole blood)

    Area under the concentration-time curve (AUC) from; * time zero to the last non-zero concentration (AUC 0-t), * time zero extrapolated to infinity (AUC 0-inf), * maximum observed concentration (Cmax)

    Time frame: Day 1 and Day 7

  2. Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N) in colonic mucosa

    Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N)in colonic mucosal tissue

    Time frame: Day 2 or Day 7

Secondary outcomes

  1. Safety and Tolerability of CyCol

    Percentage of subjects with clinically significant abnormal results

    Time frame: Day 1 to Day 7

Other outcomes

  1. Amount of unchanged cyclosporine and its metabolites excreted in faeces

    To evaluate the amount (ng/g) of unchanged cyclosporine and its metabolites (AM1, AM9, AM4N) excreted in the faeces.

    Time frame: Day 1 through Day 7

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
May 5, 2014
Start
Jul 2014
Primary completionActual
Jan 2015
CompletionActual
Feb 2015
Last update
May 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02130414
Lead sponsor
Sigmoid Pharma
Responsible party
Sponsor
First posted
May 5, 2014
Start date
Jul 2014
Primary completion
Jan 2015
Completion
Feb 2015
Last update
May 19, 2015

Study contacts

Sigmoid Pharma
study director · Sigmoid Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion